Mevapenem Injection 1g (Meropenem Hydrate)

Adult administration

As meropenem hydrate, administer 0.5 to 1 g (potency) daily, divided into 2 to 3 doses administered by slow intravenous infusion over at least 30 minutes. For suspected infections in patients with pathogenic pneumonia, peritonitis, or neutropenia, administer 1 g (potency) by slow intravenous infusion every 8 hours. For cystic fibrosis and meningitis, administer 2 g (potency) by slow intravenous infusion every 8 hours.

Child administration

In pediatric patients over 3 months of age for bacterial meningitis, administer 40 mg per kg of body weight, administered by slow intravenous infusion over 30 minutes every 8 hours, depending on the pathogen's sensitivity and the patient's condition.

This drug should not be used in specific patients. For example, patients who have experienced severe allergic reactions or shock due to this medication, those taking valproate sodium, and those who have had hypersensitivity reactions to this drug or its components, or to other carbapenem or beta-lactam antibiotics, should not receive this medication. Additionally, patients with allergic predisposition, compromised kidney function, epilepsy or central nervous system disorders, severe liver dysfunction, elderly patients, infants, or those in poor overall condition should be given this medication with caution, and dosage adjustments or modifications to administration intervals may be necessary. During the administration of this drug, observe patients closely for rare occurrences of shock, anaphylaxis, skin rashes, blood abnormalities, liver and kidney dysfunction, severe colitis, or central nervous system symptoms. If abnormal symptoms occur, immediately discontinue administration and seek appropriate treatment. To prevent the emergence of resistant bacteria, it is important to conduct sensitivity testing and administer the drug for only the minimum necessary duration. Prior to administration, always check for a history of allergy to beta-lactam drugs, and during treatment, monitor for adverse reactions such as rashes. Also, regular liver function tests should be performed to check for liver damage, and if symptoms of rhabdomyolysis such as muscle pain or weakness occur, administration should be discontinued immediately. This drug may interact with other medications, especially when co-administered with probenecid, valproate, anticonvulsants, hormonal contraceptives, or warfarin. Monitor blood drug levels and coagulation status frequently during co-administration. For women who are pregnant or may become pregnant, the safety of this drug has not been established, and it should only be administered if the benefits outweigh the risks. Nursing mothers are advised to avoid breastfeeding due to the possibility of this drug being excreted in breast milk. The safety and efficacy for infants less than 3 months old have not been established, and elderly patients have an increased risk of adverse effects due to diminished physical function, so dosage and administration intervals should be carefully adjusted and monitored closely. This drug is primarily used as a parenteral medication and should be used as soon as possible after reconstitution; if stored, proper temperature and time guidelines should be followed. Finally, this drug may have cross-reactivity with other beta-lactam antibiotics, so caution is warranted in patients with a history of allergies.

Serious side effects

Shock, anaphylaxis, severe allergic reactions, severe skin reactions (toxic epidermal necrolysis, Lyell's syndrome, Stevens-Johnson syndrome, DRESS syndrome, erythema multiforme, acute generalized exanthematous pustulosis), severe rashes with high fever, blisters, skin peeling, pain in oral/eye mucosa, asthma, dyspnea, respiratory difficulties, jaundice, liver abnormalities, profound lethargy, fulminant hepatitis, hepatic failure.

Mild side effects

• Rash
• urticaria
• warmth
• erythema
• itching
• fever
• flushing
• generalized rash
• angioedema
• oral discomfort

This drug should be stored in a sealed container to prevent contact with air and is best kept at room temperature between 1°C and 30°C. This will help maintain the drug's efficacy for an extended period.

Appearance

A crystalline powder in a colorless transparent vial, ranging from white to light yellow.

Package unit

10 vials